Back to Results

NanoViricides Inc (NNVC)

NanoViricides Inc. is a clinical-stage biotechnology company focused on developing nano-biopharmaceutical drugs aimed at viral infections. Its pipeline centers on NV-387, which has been studied for respiratory indications such as RSV and influenza and has also been formulated for COVID-related applications, including oral and injectable forms under clinical evaluation. The company is also developing NV-HHV-1 for shingles-related skin treatment and for HSV-1 and HSV-2 indications, along with additional candidates under its HIVCide program targeting diseases such as dengue and Ebola. NanoViricides was incorporated in 2005 and is headquartered in Shelton, Connecticut.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NYSE-NNVC
$1.38
-18.0% Downside
Overvalued
$6
257.1% Upside
Bargain
Fair
—
—
—
0.0%
September 2, 2026
-4.8x
4.2x
—
39.866 M
35.263 M
0.0%
97.4%
-1.9
—
91.1%
Send a message
Valuation • Fair Value

NanoViricides Inc (NYSE-NNVC) Fair Value by Valuation Model

Compare the primary fair value estimate for NanoViricides Inc (NYSE-NNVC) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$1.38

Estimated downside of 18.0% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

NM

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$1.38

Comparable-company valuation reference.

Analyst Price Target

$6

Analysts imply upside of 257.1%.

How to read these valuation models

Use this section to compare the primary fair value estimate for NanoViricides Inc (NYSE-NNVC) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for NanoViricides Inc (NYSE-NNVC)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

Not available

Data is currently unavailable.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-7.619 M

Current operating profitability reference.

EBITDA Forecast

Not available

Data is currently unavailable.

How to read profitability and growth

This section helps investors review NanoViricides Inc (NYSE-NNVC) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for NanoViricides Inc (NYSE-NNVC)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

4

Mid-range quality score.

Beneish M-Score

NM

Forensic accounting screen.

Altman Z-Score

-1.9

Lower score that deserves closer risk review.

FCF / Net Income

91.1%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for NanoViricides Inc (NYSE-NNVC). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for NanoViricides Inc (NYSE-NNVC)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

September 2, 2026

Days to Earnings

43

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for NanoViricides Inc (NYSE-NNVC), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

NanoViricides Inc (NYSE-NNVC) Stock Forecast & Technical Outlook

Review NanoViricides Inc (NYSE-NNVC) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for NanoViricides Inc (NYSE-NNVC) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for NanoViricides Inc (NYSE-NNVC) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for NanoViricides Inc (NYSE-NNVC) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for NanoViricides Inc (NYSE-NNVC) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for NanoViricides Inc (NYSE-NNVC) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for NanoViricides Inc (NYSE-NNVC)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, NanoViricides Inc (NYSE-NNVC) has a Strong Buy consensus, with 2 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 2
Hold 0
Sell 0
FAQ • Fast Investor Answers

NanoViricides Inc (NYSE-NNVC) Stock FAQ

Quick answers about NanoViricides Inc (NYSE-NNVC) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$1.38
Estimated downside 18.0%
Valuation Rating
Overvalued
Estimated downside of 18.0%
Analyst Target
$6
Implied upside 257.1%
Financial Health
Fair
Current financial-health read

The current fair value estimate for NanoViricides Inc (NYSE-NNVC) is $1.38. This implies an estimated downside of 18.0% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 18.0% versus the current market price.

The available analyst price target for NanoViricides Inc (NYSE-NNVC) is $6. The analyst target implies estimated upside of 257.1%.

The current financial health read for NanoViricides Inc (NYSE-NNVC) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for NanoViricides Inc (NYSE-NNVC) is September 2, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for NanoViricides Inc (NYSE-NNVC) is -4.8x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for NanoViricides Inc is 39.866 M.

The current enterprise value listed for NanoViricides Inc is 35.263 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for NanoViricides Inc is NYSE-NNVC, and the stock is listed on NYSE.

NanoViricides Inc (NYSE-NNVC) is listed on NYSE.

The current debt-to-total-capital ratio listed for NanoViricides Inc is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for NanoViricides Inc is 97.4%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks on NYSE View more

AbbVie Inc (ABBV) AbbVie Inc (ABBV)
Arcus Biosciences Inc (RCUS) Arcus Biosciences Inc (RCUS)
Biohaven Pharmaceutical Holding Co Ltd (BHVN) Biohaven Pharmaceutical Holding Co Ltd (BHVN)
Evommune Inc (EVMN) Evommune Inc (EVMN)
Emergent Biosolutions Inc (EBS) Emergent Biosolutions Inc (EBS)
Perspective Therapeutics Inc (CATX) Perspective Therapeutics Inc (CATX)
Lineage Cell Therapeutics Inc (LCTX) Lineage Cell Therapeutics Inc (LCTX)
Protalix Biotherapeutics Inc (PLX) Protalix Biotherapeutics Inc (PLX)
Armata Pharmaceuticals Inc (ARMP) Armata Pharmaceuticals Inc (ARMP)
Adc Therapeutics SA (ADCT) Adc Therapeutics SA (ADCT)
Pelthos Therapeutics Inc (PTHS) Pelthos Therapeutics Inc (PTHS)
Maia Biotechnology Inc (MAIA) Maia Biotechnology Inc (MAIA)
Annovis Bio Inc (ANVS) Annovis Bio Inc (ANVS)
OS Therapies Inc (OSTX) OS Therapies Inc (OSTX)
Serina Therapeutics Inc (SER) Serina Therapeutics Inc (SER)
Apimeds Pharma US Ltd (APUS) Apimeds Pharma US Ltd (APUS)
Actinium Pharmaceuticals Inc (ATNM) Actinium Pharmaceuticals Inc (ATNM)
CEL-SCI Corp (CVM) CEL-SCI Corp (CVM)
Theriva Biologics Inc (TOVX) Theriva Biologics Inc (TOVX)
Regentis Biomaterials Ltd (RGNT) Regentis Biomaterials Ltd (RGNT)
Aeon Biopharma Inc (AEON) Aeon Biopharma Inc (AEON)
Can Fite Biopharma Ltd ADR (CANF) Can Fite Biopharma Ltd ADR (CANF)
Kairos Pharma Ltd (KAPA) Kairos Pharma Ltd (KAPA)
AIM ImmunoTech Inc (AIM) AIM ImmunoTech Inc (AIM)